CRISPR Therapeutics AG CRSP shares moved lower Tuesday after the biotechnology company outlined plans to raise capital ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

ARK Invest purchased ~281K CRISPR Therapeutics (CRSP) shares worth $14.82M after a 10% drop triggered by a $350M private offering announcement.

This article looks at the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026. ARK Investment Management LLC, or ARK Invest, is an American investment management firm that oversees several ...

CRISPR Therapeutics recently reported that rollout of its approved gene therapy Casgevy for sickle cell disease and transfusion‑dependent beta thalassemia has been slower than hoped, contributing to a ...

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its ...

In the latest close session, CRISPR Therapeutics AG (CRSP) was down 5.44% at $49.93. This move lagged the S&P 500's daily loss of 0.08%. On the other hand, the Dow registered a loss of 0.61%, and the ...

Celestica has delivered strong revenue and EPS growth, driven by AI and cloud infrastructure demand. Click here to read why ...

CRISPR Therapeutics AG (NASDAQ: CRSP) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On February 17, Morgan Stanley increased its price target on CRISPR Therapeutics AG ...

Cathie Wood, head of Ark Investment Management, likes to make bold bets, even when the stocks she picks are down for a while.

Detailed price information for Hon Hai Precson S/Gdr New (HNHPF) from The Globe and Mail including charting and trades.